Esposito, Mark https://orcid.org/0000-0002-5724-4087
Fang, Cao
Cook, Katelyn C. https://orcid.org/0000-0001-5707-7592
Park, Nana
Wei, Yong https://orcid.org/0000-0002-1034-649X
Spadazzi, Chiara https://orcid.org/0000-0001-6710-5980
Bracha, Dan
Gunaratna, Ramesh T. https://orcid.org/0000-0002-8872-9984
Laevsky, Gary
DeCoste, Christina J.
Slabodkin, Hannah
Brangwynne, Clifford P. https://orcid.org/0000-0002-1350-9960
Cristea, Ileana M.
Kang, Yibin https://orcid.org/0000-0002-1626-6730
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (F31CA192461, F31AI147637, T32GM007388, R01GM114141)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA212410)
U.S. Department of Defense (BC123187)
Article History
Received: 16 June 2020
Accepted: 26 January 2021
First Online: 9 March 2021
Competing interests
: M.E. holds equity interest in KayoThera. Y.K. holds equity interest in KayoThera and Firebrand Therapeutics.